0000950170-23-036440.txt : 20230801 0000950170-23-036440.hdr.sgml : 20230801 20230801160200 ACCESSION NUMBER: 0000950170-23-036440 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230801 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230801 DATE AS OF CHANGE: 20230801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioAtla, Inc. CENTRAL INDEX KEY: 0001826892 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 851922320 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39787 FILM NUMBER: 231131556 BUSINESS ADDRESS: STREET 1: 11085 TORREYANA ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-558-0708 MAIL ADDRESS: STREET 1: 11085 TORREYANA ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 bcab-20230801.htm 8-K 8-K
false0001826892BioAtla, Inc.00018268922023-08-012023-08-01

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 01, 2023

 

 

BIOATLA, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39787

85-1922320

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

11085 Torreyana Road

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 858 558-0708

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

BCAB

 

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 2.02 Results of Operations and Financial Condition.

On August 1, 2023, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023 and provided an update on its ongoing clinical programs. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The information set forth in Item 2.02 of this Current Report on Form 8-K (“Current Report”), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information set forth in Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

Description

99.1

Press Release dated August 1, 2023

104

Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

BioAtla, Inc.

 

 

 

 

Date:

August 1, 2023

By:

/s/ Richard Waldron

 

 

 

Richard Waldron
Chief Financial Officer

 


EX-99.1 2 bcab-ex99_1.htm EX-99.1 EX-99.1

 

BIOATLA REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS

AND HIGHLIGHTS RECENT PROGRESS
 

 

Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS)

 

Submitted Food & Drug Administration (FDA) meeting request for potentially registrational study of BA3011 in non-small cell lung cancer (NSCLC) study; FDA feedback and initiation of study remain on track for 2H23

Continuing to enroll BA3021 Phase 2 NSCLC, melanoma and squamous cell carcinoma of the head & neck (SSCHN) studies; anticipate data across indications to prioritize and make a 'go' decision in 2H2023

 

Cleared fifth cohort at 5 mg/kg monotherapy and in combination with PD-1 in Phase 1 dose-escalation CAB-CTLA-4 (BA3071) study with no dose-limiting toxicities (DLTs) reported; currently enrolling patients in sixth cohort at 10 mg/kg; anticipated Phase 1 data readout and initiation of Phase 2 remain on track for 2H23

 

Cash balance of $168.7 million expected to provide funding into 2025

Management to host conference call and webcast today at 4:30 PM Eastern Time

 

SAN DIEGO, August 1, 2023 – BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the second quarter ended June 30, 2023, and provided highlights on its clinical programs.

“BioAtla continues to progress our robust CAB pipeline, including the recent clearance of the fifth cohort with no DLTs observed in our Phase 1 BA3071 CTLA-4 study,” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. “BioAtla has several important near-term value inflection points, including data readouts in the second half of this year. Additionally, we anticipate FDA feedback for our Phase 2, part 2 potentially registrational BA3011 trial in NSCLC, and initiation of our Phase 2 CAB-CTLA-4 BA3071 trial in multiple indications. We continue to work diligently to progress our programs while managing our resources to preserve cash into 2025.”

Key Developments, Operational Updates and Upcoming Milestones

Phase 2 Trial of Mecbotamab Vedotin in Patients with:
AXL-positive Soft Tissue and Primary Bone Sarcomas (BA3011, NCT03425279)
Phase 2, part 1:
Continuing to enroll remaining cohorts
LMS cohort data readout remains on track for 2H23 using a more frequent, dose-intensive regimens
Phase 2, part 2:

Continuing to enroll and dose patients in potentially registrational Phase 2 UPS study
AXL-positive NSCLC (BA3011, NCT04681131)
Phase 2, part 1:
Continuing to enroll more frequent, dose-intensive regimens; anticipated data for all dosing regimens to enable decision on selected dose for Phase 2, part 2 remains on track for 2H23
Phase 2, part 2 (potentially registrational):
Submitted meeting request to the FDA for the study design; anticipate FDA feedback in 2H23
Initiation of study on track for 2H23
AXL-positive platinum-resistant ovarian cancer (BA3011, NCT04918186)
Phase 2 investigator-initiated trial is on track with interim data (n=10) anticipated in 2H23

Phase 2 Trials of Ozuriftamab Vedotin in Patients with:
ROR2-positive NSCLC (BA3021, NCT03504488)
Continuing to enroll in the more frequent, dose-intensive regimen
ROR2-positive melanoma (BA3021, NCT03504488)
Identified ROR2-positive tumors using liquid biopsy assay
Anticipate dosing patients in 2H23
ROR2-positive SCCHN (BA3021, NCT05271604)
Multiple patients dosed and continuing to enroll patients
ROR2-positive platinum-resistant ovarian cancer (BA3021, NCT04918186)
Phase 2 investigator-initiated trial is on track with interim data (n=10) anticipated in 2H23
Anticipated data across indications to prioritize and make a 'go' decision for indications to further pursue remains on track for 2H23

 

Phase 1/2 dose-escalation trial of CAB-CTLA-4 (BA3071, NCT05180799) across multiple solid tumor types responsive to CTLA-4
DLT observation period cleared for fifth cohort (350 mg [5 mg/kg]) as monotherapy and in combination with nivolumab 3 mg/kg every three weeks (Q3W)
Enrolling 700 mg (10mg/kg) as sixth dose cohort as monotherapy and in combination with nivolumab 3mg/kg Q3W
Anticipated Phase 1 data readout remains on track for 2H23
Initiation of the Phase 2 part of the study remains on track for 2H23

 

Phase 1/2 dose-escalation for CAB-EpCAM x CAB-CD3 TCE (BA3182)
Enrolling Phase 1 study for the treatment of advanced adenocarcinoma
Anticipated completion of Phase 1 data readout remains on track in 2024

 

 

Since the first quarter, two additional accepted and upcoming poster presentations for trials in progress (for BA3011 and BA3021) at the upcoming World Conference on Lung Cancer (WCLC), to be held September 9-12, titled:

“A Phase 2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination with Nivolumab”
“A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab”

 

Second Quarter 2023 Financial Results

Cash and cash equivalents as of June 30, 2023 were $168.7 million, compared to $215.5 million as of December 31, 2022. We expect current cash and cash equivalents will be sufficient to fund planned operations including all ongoing CAB product development programs into 2025.

Research and development (R&D) expenses were $31.0 million for the quarter ended June 30, 2023 compared to $20.7 million for the same quarter in 2022. The increase of $10.3 million was primarily driven by our preclinical and clinical product development efforts. We expect our R&D expenses to remain variable from quarter to quarter and generally increase as we continue to invest in R&D activities to advance our product candidates and our clinical programs.

General and administrative (G&A) expenses were $6.2 million for the quarter ended June 30, 2023 compared to $8.3 million for the same quarter in 2022. The $2.1 million change was attributable to a decrease in various administrative expenses for the 2023 period. We expect our G&A expenses to moderately increase to support development of our product candidates, advance our intellectual property portfolio, support focused pre-commercialization activities for our product candidate mecbotamab vedotin (BA3011) and satisfy requirements as a public company.

Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the same quarter in 2022.

Net cash used in operating activities for the months ended June 30, 2023 was $46.7 million compared to net cash used in operating activities of $42.1 million for the same period in 2022. The increase in net cash used in operating activities for the first six months of 2023 is primarily due to an increase in research and development expense related to our program development efforts as compared to the first six months of 2022.

Second Quarter 2023 Conference Call and Webcast Details

The management of BioAtla, Inc. will host a conference call and webcast for the investment community today, August 1, 2023, at 4:30 pm Eastern Time. A live webcast may be accessed here: https://viavid.webcasts.com/starthere.jsp?ei=1619442&tp_key=871a8141a7. The conference call can be accessed by dialing toll-free (877) 425-9470 or (201) 389-0878 (international). The passcode for the conference call is 13739244.

 

A replay of the webcast and slides with topline interim clinical data referenced on the call will be available through “Events & Presentations” in the Investors section of the company’s website after the conclusion of the presentation and will be archived on the BioAtla website for one year.

About Mecbotamab Vedotin (BA3011)

Mecbotamab vedotin, CAB-AXL-ADC, is a conditionally and reversibly active antibody drug conjugate targeting the receptor tyrosine kinase AXL. This Phase 2 stage clinical asset is targeting multiple solid tumor types, including soft tissue and bone sarcoma and non-small cell lung cancer (NSCLC) that have previously progressed on PD-1/L1, EGFR or ALK inhibitor therapies. We are also supporting a multi-center


investigator-initiated clinical trial in combination with durvalumab, a PD-L1-blocking antibody, in patients with platinum-resistant ovarian cancer, in addition to other potential indications in the future. The Office of Orphan Drug Products (OODP) at FDA granted Orphan Drug Designation to mecbotamab vedotin for the treatment of soft tissue sarcoma.

About Ozuriftamab Vedotin (BA3021)

Ozuriftamab vedotin, CAB-ROR2-ADC, is a conditionally and reversibly active antibody drug conjugate directed against ROR2, a receptor tyrosine kinase that is overexpressed across many different solid tumors including lung, head and neck and melanoma. We are advancing this Phase 2 stage clinical asset for multiple solid tumor types, including NSCLC that have previously progressed on PD-1/L1, EGFR or ALK inhibitor therapies, melanoma that have previously progressed on PD-1/L1 therapy and SCCHN that have previously progressed on PD-1/L1 therapies with or without platinum chemotherapy. We are also supporting a multi-center investigator-initiated clinical trial in combination with durvalumab, a PD-L1-blocking antibody, in patients with platinum-resistant ovarian cancer, in addition to other potential indications in the future.

About BA3071

BA3071, is a CAB anti-CTLA-4 antibody that is being developed as an immuno-oncology agent with the goal of delivering efficacy at least comparable to the approved anti-CTLA-4 antibodies, but with lower toxicities due to the CAB's tumor microenvironment-restricted activity. This may enable safer anti-CTLA-4 antibody combination therapies, such as with anti-PD-1 antibody checkpoint inhibitors, and potentially broaden the patient population tolerant to combination therapy and deliver greater efficacy. Like our other CAB candidates, BA3071 is designed to be conditionally and reversibly active in the tumor microenvironment. BA3071 is being developed as a potential therapeutic for multiple solid tumor indications that are known to be responsive to CTLA-4 treatment in combination with a PD-1 blocking agent.

 

About BA3182

BioAtla is developing BA3182 as a potential anticancer therapy for patients with advanced adenocarcinoma. BA3182 is a conditionally active biologic (CAB) EpCAM/CD3 bispecific T cell engager antibody that contains two binding sites for EpCAM and two binding sites for CD3ε. The binding sites for EpCAM and CD3ε have been designed to bind their respective targets specifically and reversibly under the conditions found in the TME and to have reduced binding outside of the TME. The CAB selective binding to both the CAB EpCAM and CAB CD3ε arms are required to activate the T cell engagement against the tumor, thus enabling the combined selectivity of each CAB binding arm in the bispecific antibody. BioAtla recently received FDA IND clearance to conduct a first-in-human, Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of BA3182 in advanced adenocarcinoma patients.

About EpCAM

EpCAM is involved in the maintenance of epithelial integrity, and its expression is associated with proliferation during morphogenesis, tissue regeneration, and stem cell maintenance. Expression levels of EpCAM vary amongst different organs and cell types, with epithelia of colon, small intestine, lung, pancreas, liver and gall bladder expressing the highest levels of EpCAM protein. Given the functions and properties of EpCAM protein, high levels of EpCAM expression have been found in many carcinomas. EpCAM is highly and frequently expressed in the vast majority of carcinomas and their metastasis and has been considered as a potential prognostic and therapeutic marker for many carcinomas.



About BioAtla®, Inc.

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 700 patents filed, more than 400 of which have been issued. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 1 stage CAB-CTLA-4 antibody, BA3071, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first bispecific antibody, BA3182, targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com.

Forward-looking statements

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words. Examples of forward-looking statements include, among others, statements we make regarding our business plans and prospects, including our plans to initiate and advance a Phase 1 dose-escalation and expansion clinical study for BA3182, whether our clinical trials will support registration; achievement of milestones; results, conduct, progress and timing of our research and development programs and clinical trials; expectations with respect to enrollment and dosing in our clinical trials, plans and expectations regarding future data updates, clinical trials, regulatory meetings and regulatory submissions; the potential regulatory approval path for our product candidates; expectations about the sufficiency of our cash and cash equivalents; and expected R&D and G&A expenses. Forward-looking statements are based on BioAtla's current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: potential delays in clinical and pre-clinical trials due to the global COVID-19 pandemic; other potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, or regulatory approval dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; whether regulatory authorities will be satisfied with the design of and results from the clinical studies or take favorable regulatory actions based on results from the clinical studies; our dependence on the success of our CAB technology platform; our ability to enroll patients in our ongoing and future clinical trials; the success of our current and future collaborations with third parties; our reliance on third parties for the manufacture and supply of our


product candidates for clinical trials; our reliance on third parties to conduct our clinical trials and some aspects of our research and preclinical testing; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 23, 2023, in our Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023 and August 1, 2023 and our other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and BioAtla undertakes no duty to update such information except as required under applicable law.

Internal Contact:

Richard Waldron

Chief Financial Officer

BioAtla, Inc.

rwaldron@bioatla.com

858.356.8945

External Contact:
Bruce Mackle

LifeSci Advisors, LLC

bmackle@lifesciadvisors.com

 

 

 

 


BioAtla, Inc.

Unaudited Condensed Statements of Operations and Comprehensive Loss

(in thousands)

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2023

 

2022

 

 

2023

 

2022

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development expense

$

30,960

 

$

20,711

 

 

$

52,657

 

$

37,634

 

General and administrative expense

 

6,241

 

 

8,344

 

 

 

13,474

 

 

15,767

 

Total operating expenses

 

37,201

 

 

29,055

 

 

 

66,131

 

 

53,401

 

Loss from operations

 

(37,201

)

 

(29,055

)

 

 

(66,131

)

 

(53,401

)

Other income (expense):

 

 

 

 

 

 

 

 

 

Interest income

 

1,460

 

 

146

 

 

 

2,940

 

 

231

 

Other income (expense)

 

(11

)

 

3

 

 

 

(21

)

 

10

 

Total other income (expense)

 

1,449

 

 

149

 

 

 

2,919

 

 

241

 

Net loss and comprehensive loss

$

(35,752

)

$

(28,906

)

 

$

(63,212

)

$

(53,160

)

 

BioAtla, Inc.

Condensed Consolidated Balance Sheets Data

(in thousands)

 

 

 

June 30,
2023

 

 

December 31,
2022

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

168,693

 

 

$

215,507

 

Total assets

 

 

179,637

 

 

 

225,736

 

Total current liabilities

 

33,653

 

 

23,131

 

Total liabilities

 

 

55,121

 

 

 

45,397

 

Total stockholders’ equity

 

 

124,516

 

 

 

180,339

 

Total liabilities and stockholders’ equity

 

 

179,637

 

 

 

225,736

 

 

 


EX-101.LAB 3 bcab-20230801_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 4 bcab-20230801_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 5 bcab-20230801.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Aug. 01, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 01, 2023
Entity Registrant Name BioAtla, Inc.
Entity Central Index Key 0001826892
Entity Emerging Growth Company false
Securities Act File Number 001-39787
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 85-1922320
Entity Address, Address Line One 11085 Torreyana Road
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 558-0708
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol BCAB
Security Exchange Name NASDAQ
XML 7 bcab-20230801_htm.xml IDEA: XBRL DOCUMENT 0001826892 2023-08-01 2023-08-01 false 0001826892 BioAtla, Inc. 8-K 2023-08-01 DE 001-39787 85-1922320 11085 Torreyana Road San Diego CA 92121 858 558-0708 false false false false Common Stock, $0.0001 par value per share BCAB NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - bcab-20230801.htm 8 bcab-20230801.htm bcab-20230801.xsd bcab-20230801_lab.xml bcab-20230801_pre.xml bcab-ex99_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bcab-20230801.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "bcab-20230801.htm" ] }, "labelLink": { "local": [ "bcab-20230801_lab.xml" ] }, "presentationLink": { "local": [ "bcab-20230801_pre.xml" ] }, "schema": { "local": [ "bcab-20230801.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bcab", "nsuri": "http://www.bioatla.com/20230801", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "bcab-20230801.htm", "contextRef": "C_f8ceee8d-d09f-4fe7-9939-0398b481dc1f", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "bcab-20230801.htm", "contextRef": "C_f8ceee8d-d09f-4fe7-9939-0398b481dc1f", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.bioatla.com/20230801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000950170-23-036440-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-036440-xbrl.zip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end